Encompass Health Corporation (NYSE:EHC) Stock Has Average Price Target of $148.50

Encompass Health Corporation (NYSE:EHC) has received a consensus rating of “Buy” from the seven ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $148.50.

A number of research analysts have recently commented on EHC shares. Barclays raised their price target on Encompass Health from $140.00 to $144.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. TD Cowen upped their target price on Encompass Health from $125.00 to $140.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. UBS Group increased their price target on Encompass Health from $150.00 to $155.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Raymond James Financial set a $150.00 price target on Encompass Health in a research report on Monday, September 28th. Finally, Truist Financial boosted their price objective on Encompass Health from $140.00 to $150.00 and gave the stock a “buy” rating in a research note on Friday, August 7th.

Insider Transactions at Encompass Health

In other Encompass Health news, CEO Mark Tarr sold 173,148 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $125.47, for a total value of $21,724,879.56. Following the sale, the chief executive officer directly owned 267,814 shares in the company, valued at approximately $33,602,622.58. The trade was a 39.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP John Darby sold 8,906 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $125.95, for a total value of $1,121,710.70. Following the completion of the transaction, the executive vice president directly owned 75,041 shares in the company, valued at $9,451,413.95. This represents a 10.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 186,912 shares of company stock worth $23,434,845. 1.80% of the stock is owned by corporate insiders.

Institutional Trading of Encompass Health

A number of hedge funds have recently modified their holdings of the business. Transamerica Financial Advisors LLC acquired a new stake in shares of Encompass Health during the 2nd quarter valued at $29,000. Toth Financial Advisory Corp purchased a new stake in shares of Encompass Health during the third quarter worth $38,000. Persistent Asset Partners Ltd purchased a new stake in shares of Encompass Health during the second quarter worth $36,000. Keating Financial Advisory Services Inc. acquired a new stake in Encompass Health during the second quarter valued at $39,000. Finally, Assetmark Inc. boosted its position in Encompass Health by 89.6% during the first quarter. Assetmark Inc. now owns 455 shares of the company’s stock valued at $44,000 after purchasing an additional 215 shares during the last quarter. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Encompass Health Stock Performance

Encompass Health stock opened at $127.69 on Monday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.19 and a current ratio of 1.19. Encompass Health has a one year low of $92.77 and a one year high of $129.96. The stock’s 50 day moving average price is $122.51 and its 200 day moving average price is $111.56. The firm has a market capitalization of $12.60 billion, a PE ratio of 20.80, a price-to-earnings-growth ratio of 2.59 and a beta of 0.74.

Encompass Health (NYSE:EHC) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.48 by $0.07. Encompass Health had a net margin of 10.01% and a return on equity of 18.08%. The business had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period in the previous year, the business posted $1.40 EPS. The company’s quarterly revenue was up 9.6% on a year-over-year basis. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. As a group, sell-side analysts expect that Encompass Health will post 6.08 EPS for the current fiscal year.

Encompass Health Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, October 15th. Investors of record on Thursday, October 1st were issued a dividend of $0.21 per share. The ex-dividend date of this dividend was Thursday, October 1st. This is an increase from Encompass Health’s previous quarterly dividend of $0.19. This represents a $0.84 dividend on an annualized basis and a yield of 0.7%. Encompass Health’s dividend payout ratio is presently 13.68%.

Encompass Health Company Profile

Encompass Health Corporation (NYSE:EHC) is a healthcare services company focused on inpatient rehabilitation. Through its network of rehabilitation hospitals, the company provides intensive medical and therapeutic care to patients recovering from conditions such as strokes, brain and spinal cord injuries, hip fractures, amputations, neurological disorders, and other disabling illnesses or injuries.

Its rehabilitation hospitals offer coordinated care from physicians, nurses, therapists, and other healthcare professionals.